GET THE APP

Cell & Developmental Biology

Cell & Developmental Biology
Open Access

ISSN: 2168-9296

+44 1478 350008

Cell & Developmental Biology : Citations & Metrics Report

Articles published in Cell & Developmental Biology have been cited by esteemed scholars and scientists all around the world. Cell & Developmental Biology has got h-index 15, which means every article in Cell & Developmental Biology has got 15 average citations.

Following are the list of articles that have cited the articles published in Cell & Developmental Biology.

  2022 2021 2020 2019 2018

Year wise published articles

30 30 26 5 8

Year wise citations received

123 142 124 118 105
Journal total citations count 951
Journal impact factor 5.1
Journal 5 years impact factor 6.8
Journal cite score 7.0
Journal h-index 15
Journal h-index since 2018 12
Important citations (614)

Lu dy, lu tr, cao s, yarla ns, lu y. life origin on earth, what is the right answer. int j mol biol open access. 2017;2(2):00017.

Lu dy, wu hy, lu tr, che jy, lu y. updating biomedical studies by recruiting more mathematics or physics-majored talents. metabolomics. 2016;6(2):e148.

Košarić j. ispitivanje molekularnih mehanizama dejstva nekih organoselenskih jedinjenja na redoks status ćelija kancera kolona nst-116 i dojke mda-mb-2314 (doctoral dissertation, Универзитет у Крагујевцу, Природно-математички факултет).

Elbur ai, yousif ma, albarraq aa, abdallah ma. pharmacy practice & drug research.

Kundu a, dey p, banerjee s, sarkar p, de a, maity a, kim hs. 5 heparin and its derivatives-based nanoparticles for cancer therapy. polysaccharide based nano-biocarrier in drug delivery. 2018 sep 3:81-104.

Dasgupta s, roy s, chakraborty t, sarkar n. polysaccharide-based nanocarriers loaded with drugs for the management of obesity. inpolysaccharide based nano-biocarrier in drug delivery 2018 sep 3 (pp. 339-360). crc press.

Lu dy, lu tr, xu b, varki a, huang m, zhu h, shen y, yarla ns. aberrant sialylation in cancer pathology and metastasis, a putative drug target candidate. anti-cancer agents in medicinal chemistry (formerly current medicinal chemistry-anti-cancer agents). 2018 nov 1;18(14):1952-61.

Hassan ba. concepts of anticancer treatment and pharmacogenomics in cancer treatments. frontiers in anti-cancer drug discovery. 2015 may 5;5:64.

Lu dy, chen eh, lu tr, ding j, xu b. innovations in pharmaceuticals and pharmacotherapy.

Lu dy, lu tr, wu hy. journal of clinical and experimental pharmacology.

Mahasa kj. mathematical modelling of drug resistance in malignant tumour treatment (doctoral dissertation).

Lu dy, lu tr, chen eh, yarla ns, xu b, ding j, huang m, zhu h. keep u p the pace of drug development evolution and expenditure. cancer rep rev. 2018 sep 26;2(5):165.

Lu dy, lu tr, xu b, che jy, wu sy, wu hy, yarla ns. anti-metastatic drug development, work out towards new direction. med chem (los angeles). 2018;8:192-6.

Lu dy, lu tr, xu b, ding j, chen eh, wu hy, wu sy, yarla ns, zhu h. antimetastatic therapy at aberrant sialylation in cancer cells, a potential hotspot. clin. proteom. bioinform. 2017;2(1):118.

Lu dy, lu tr, xu b, ding j, lu y, yarla ns. perspective of personalized cancer therapy. drug therapy. 2017;10(1):44-55.

Lu dy, lu tr, xu b, che jy, shen y, yarla ns. individualized cancer therapy, future approaches. current pharmacogenomics and personalized medicine (formerly current pharmacogenomics). 2018 jun 1;16(2):156-63.

Lu dy, lu tr, xu b, ding j, yarla ns. general topics in the field of personalized cancer therapy. metabolomics (los angels). 2018;8:e156.

Lu dy, lu tr, xu b, ding j, yarla ns. clinical cancer therapy, personalized chemotherapies. j cell dev biol. 2017;1(1):5.

Lu dy, qu rx, lu tr, wu hy. cancer bioinformatics for updating anticancer drug developments and personalized therapeutics. reviews on recent clinical trials. 2017 jun 1;12(2):101-10.

Lu dy, xu j, lu tr, wu hy, xu b. inhibitions of several antineoplastic drugs on serum sialic acid levels in mice bearing tumors. scientia pharmaceutica. 2013 mar;81(1):223-32.

Top